stride semaglutide Best of ACC 2025 and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE) Semaglutide increased walking distance in patients with symptomatic peripheral artery disease and Stephanie Saucier MD, FACC |

Across these studies, weight loss was consistently greater with semaglutide than with placebo, and the weight loss was associated with improvements in cardiometabolic risk factors including blood pressure, waist circumference, lipid profiles, and inflammatory markers

Healthcare providers should never assume concentration equivalence between different semaglutide products and should always confirm the specific product concentration before providing dosing instructions

Like all treatments, Semaglutide GLP-1 can cause side effects such as constipation, diarrhea, and nausea, which usually subside as the body adjusts

Biological systems interact in ways that isolated pathway analysis cannot fully predict